| Name | CL097 |
| Description | CL097 is an effective agonist of TLR7 and TLR8. CL097 induces pro-inflammatory cytokines in macrophages and NADPH oxidase priming, thereby increasing the fMLF-stimulated ROS production. |
| In vitro | CL097 (0, 0.5, 2.5, 5, and 10 μg/mL) induces hyperactivation of the NADPH oxidase by stimulating the phosphorylation of p47phox on selective sites in human neutrophils[1]. CL097 (0.1 μM) induces activation of NF-κB in TLR7-transfected HEK293 cells and at 4 μM in TLR8-transfected HEK293 cells[3]. |
| In vivo | in NOD mice, CL097 (5 mg/kg, s.c.) causes a modest specific lysis of the target peptide (∼25%). However, treatment with a combination of CL097 and CD40 agonist (10 mg/kg, i.p.) results in an increase of approximately twofold in the specific lysis of the IGRP-peptide-coated targets compared with CL097 treatment alone[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 95 mg/mL (392.11 mM), Sonication is recommended.
|
| Keywords | Immunological | CL-097 | inhibit | Oligonucleotide | Toll-like Receptor (TLR) | Peptide | TLR7 | Heterocycle | modulators | Inhibitor | CL 097 | Reactive Oxygen Species | TLR8 |
| Inhibitors Related | Sodium Thiocyanate | Imeglimin hydrochloride | Acetylcysteine | L-Ascorbic acid | α-Vitamin E | Hydroxychloroquine | Chloroquine phosphate | Glucosamine | D-(+)-Glucono-1,5-lactone | Chloranil | Lycopene | Naringenin |
| Related Compound Libraries | NF-κB Signaling Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Ovarian Cancer Compound Library | Anti-Breast Cancer Compound Library | Pyroptosis Compound Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library |
United States
